Genetic analyses have shaped much of our understanding of cancer. However, it is
becoming increasingly clear that cancer cells display features of normal tissue organization …

CD47 is a broadly expressed membrane protein that interacts with the myeloid inhibitory
immunoreceptor SIRPα (also termed CD172a or SHPS-1). SIRPα is the prototypic member …

Tumor recurrence following treatment remains a major clinical challenge. Evidence from
xenograft models and human trials indicates selective enrichment of cancer-initiating cells …

Resistance to tumor therapy is an unsolved problem in cancer treatment. A plethora of
studies have attempted to explain this phenomenon and many mechanisms of resistance …

Introduction Treatment failure in acute myeloid leukemia is probably caused by the presence
of leukemia initiating cells, also referred to as leukemic stem cells, at diagnosis and their …

The FLT3-ITD mutation is frequently observed in acute myeloid leukemia (AML) and is
associated with poor prognosis. In such patients, FLT3 tyrosine kinase inhibitors (TKIs) are …

Since the discovery of the “nude” mouse more than 40 years ago, investigators have
attempted to model human tumor growth in immunodeficient mice. Here, we summarize how …

Maturation of T cell–activating APCs directly links innate and adaptive immunity and is
typically triggered by microbial infection. Transplantation of allografts, which are sterile …

Although significant advances in radiotherapy have increased its effectiveness in many
cancer settings, general strategies to widen the therapeutic window between normal tissue …

Identification of therapeutic targets against tumor‐initiating cells (TICs) is a priority in the
development of new therapeutic paradigms against cancer. We enriched a TIC population …